NVS announces senior management transition: Dan Vasella, who has been CEO since the company’s formation in 1996 (the longest reign of any current Big Pharma CEO) is handing the reins to Joe Jimenez, who had been chief of NVS’ pharma division. Vasella will remain Chairman of the Board. The new head of NVS’ pharma division will be David Epstein, who had been head of oncology.
This announcement was made in conjunction with NVS’ 4Q09 financial results.
Market Data 
Markets 
AI
